An observational study in Respiratory Distress Syndrome, Preterm Birth and Acute Respiratory Distress Syndrome, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Recruiting at 1 site in China. Open to participants aged 1 Minute to 24 Hours. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University — 2 open to participants now, 2 under way, none of them phase 3. Respiratory Distress Syndrome · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.
Among the 11 studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, this one is the only one that started in 2021, is one of 2 observational ones, and was the 11th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →2 of the 11 studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University are open now, in 1 country. Recruiting first, the newest first:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 1 min–1 hrs
By country, each count listing its studies:
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 1 Minute to 24 Hours · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 300 across the 9 interventional studies, 700 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University is the lead sponsor of 121 studies on the registry; 42 are open to participants now.
1 of the studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04777760Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversitySurfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and/or death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS.
In 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.
To date, PS is not recommended to adult and pediatric ARDS. Meantime, systematic review indicates that PS does not demonstrate statistically significant beneficial effects on reducing the mortality and the rate of BPD in term and late preterm infants with meconium aspiration syndrome(MAS). Therefore, a reasonable speculation is that preterm infants with NARDS do not benefit from one dose of PS. And the speculation can explain why not all preterm infants with respiratory distress can be beneficial from PS. In the era of pre-NARDS, the preterm infants fulfilling the definition of NARDS may have been considered as NRDS in the first three days after birth.
According to the diagnostic criteria of NARDS, a key procedure for diagnosis of NARDS is to exclude the newborn infants with NRDS. But no detailed procedures are available to differentiate NRDS from NARDS.
Preterm infants diagnosed with NRDS or NARDS were eligible. The diagnosis of NARDS was according to the criteria established by Montreux conference in 2017.The diagnosis of NRDS was according to the criteria established by European Consensus Guideline for the management of NRDS in 2019
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligibility requirements for neonates were as follows:
Exclusion Criteria:
one of the following criteria will be needed
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
Drug: one dose of surfactant replacement
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
Drug: two and more doses of surfactant replacement
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
bronchopulmonary dysplasia(BPD)
the preterm infants will be diagnosed with BPD
Time frame: at 36 weeks' gestational age or before discharge from hospital
death
the preterm infants die
Time frame: at 36 weeks' gestational age or before discharge from hospital
BPD and/or death
the preterm infants will be diagnosed with BPD and/or death
Time frame: at 36 weeks' gestational age or before discharge from hospital
the predictive powers of one dose of surfactant to diagnose NRDS
the sensitivity and accuracy of one dose of surfactant to diagnose NRDS
Time frame: seven days after birth
the predictive powers of two and more doses of surfactant to diagnose NARDS
the sensitivity and accuracy of two and more doses of surfactant to diagnose NARDS
Time frame: seven days after birth
intraventricular hemorrhage(IVH)
the preterm infants will be diagnosed with IVH
Time frame: before discharge or 36 weeks' gestational age
air leak
the preterm infants will be diagnosed with air leak
Time frame: at 36 weeks' gestational age or before discharge from hospital
periventricular leukomalacia(PVL)
the preterm infants will be diagnosed with PVL
Time frame: at 36 weeks' gestational age or before discharge from hospital
necrotizing enterocolitis(NEC)
the preterm infants will be diagnosed with NEC
Time frame: at 36 weeks' gestational age or before discharge from hospital
patent ductus arteriosis(PDA)
the preterm infants will be diagnosed with PDA
Time frame: at 36 weeks' gestational age or before discharge from hospital
late-onset sepsis(LOS)
the preterm infants will be diagnosed with LOS
Time frame: at 36 weeks' gestational age or before discharge from hospital
Plan to share: Yes — the data will be accessed after two years of study accomplishment
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: preliminary estimate in 2025
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 71 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University →